153 
0 Kommentare
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing
Five U.S. government proposals submitted, totalling up to US$125 million
HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2025 (“FYE 2025”), and provided an update on fiscal 2026. All figures are stated in Canadian dollars unless otherwise stated.
“The recent commercial re-launch of LIKMEZ (ATI-1501), following new patent coverage through to 2039, marked a major milestone for Appili and our partner, Saptalis Pharmaceuticals, LLC (“Saptalis”). Appili was founded to develop ATI-1501, and it’s rewarding to see our lead development program in the market,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics.
“As we look to fiscal 2026, we remain focused on driving continued sales of LIKMEZ, advancing ATI-1701 funded activities, and finalizing development plans for ATI-1801. In addition, Appili has submitted five non-dilutive funding proposals to the U.S. government, totaling up to US$125 million.”
LIKMEZ (ATI-1501), re-launched in the U.S.
In May 2025, the Company’s manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) re-launched LIKMEZ metronidazole oral suspension, (500 mg/5 mL) in the U.S. LIKMEZ is the first and only FDA-approved, ready-to-use liquid oral suspension of metronidazole, developed specifically for patients who have difficulty swallowing tablets or who are sensitive to taste.
Metronidazole is widely used as a frontline oral treatment with millions of prescriptions written in the U.S. every year. The current tablet form of metronidazole is the only other approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges. LIKMEZ is designed to fill this significant gap in the treatment paradigm with a taste-masked metronidazole oral suspension.
Diskutieren Sie über die enthaltenen Werte
URL kopieren
Per E-Mail teilen
Artikel drucken